Objectives-To survey the use of corticosteroids in multiple sclerosis as recommended by United Kingdom consultant neurologists. Methods-A postal questionnaire covering the use of corticosteroids for acute multiple sclerosis relapse and chronic progressive multiple sclerosis with regard to frequency of use, type of corticosteroid, and dosage regime was sent to all members of the Association of British Neurologists with a United Kingdom address. Results-Two hundred and twelve United Kingdom consultant neurologists replied to the survey (74% response rate). Eighty six per cent indicated that they prescribed corticosteroids in more than one quarter of acute multiple sclerosis relapses seen. Intravenous methylprednisolone was recommended at some time by 99% of consultant neurologists, the most popular regime being 1g daily for 3 days (74%; 154/ 208). Over one half (53%; 109/206) never recommended a subsequent tapering course of oral corticosteroids; of those that did, 25% (24/96) recommended a tapering course lasting more than 1 month. Eighty eight per cent (181/206) of prescribers of intravenous methylprednisolone were able to oVer the course as a day case on the ward; 7% (15/206) at an outpatient clinic; and 5% (11/206) at home. Almost three quarters of neurologists recommended oral corticosteroids for some acute relapses, although the most popular response was for occasional use only (48%; 101/212). Forty five per cent (96/211) at least occasionally recommended steroids for patients with chronic multiple sclerosis not experiencing an acute relapse. Conclusions-Although the vast majority of consultant neurologists would prescribe intravenous methylprednisolone for acute multiple sclerosis relapse at some time, the use of corticosteroids for multiple sclerosis was otherwise variable. There seemed to be little consensus about the use of oral steroids in acute relapse, the prescribing of a tapering course of oral steroids after intravenous methylprednisolone, or the utility of steroids in chronic multiple sclerosis. Variability of prescribing recommendations probably reflects a lack of clear evidence in the face of a wide range of clinical situations, variable access, and timing of access to neurologists in the acute phase of relapse and pressure on neurologists to treat in an otherwise "hopeless" situation. Large multicentred trials are needed to consider these issues. (J Neurol Neurosurg Psychiatry 1998;65:362-365) 
Corticosteroids are widely used for multiple sclerosis. An estimated 8000 to 10 000 multiple sclerosis relapses are treated with corticosteroids each year in the United Kingdom. 1 Prescribing should ideally be evidenced based, although the relevant clinical trials have utilised highly selected patients perhaps not representative of the multiple sclerosis population, insensitive outcome measures, low patient numbers, and sometimes poorly matched patient groups. This survey aimed to determine the recommendations and prescribing habits of corticosteroids for multiple sclerosis by United Kingdom consultant neurologists.
Method
After piloting a two sided questionnaire, it was sent with a covering letter and freepost return envelope to all full and associate members of the Association of British Neurologists with a United Kingdom address. Most questions were of the closed type, requiring tick box answers to reduce responder burden; a Likert scale was adopted for some questions, response options being: never, occasionally (<25% of cases), sometimes (25%-50% of cases), frequently (>50% of cases), and always. The questionnaire was anonymous, although responders could add their name and address if they wished to receive a copy of the results on completion of the study. No reminders were sent. (22/156) oral dexamethasone, and two oral prednisone. The most often endorsed oral prednisolone regime was 60 mg daily, tapering to zero over 10 to 28 days (35/156). Other regimes ranged from starting doses of 15 mg to 500 mg tapering to zero over 3 to 56 days. Six per cent (9/156) specified a tapering course lasting more than 1 month. The most popular oral methylprednisolone regimes were 500 mg daily for 5 days (44%; 16/36) and 1 g daily for 3 days (4/36). Dosage regimes of oral dexamethasone ranged from 6 to 16 mg daily for 5 to 21 days. Some recommended either of the 2 types of corticosteroid. In all 13 did not specify a dose, three of whom wrote "variable". One did not respond to the whole question.
Results

CORTICOSTEROIDS FOR CHRONIC MULTIPLE SCLEROSIS (NOT INCLUDING ACUTE RELAPSE)
The majority (55%; 115/211) said that they never used corticosteroids for patients with chronic progressive multiple sclerosis who were not in acute relapse, but 45% (96/211) would do so at times and 5% (11) would do so in more than a quarter of cases (table (e)). Intravenous methylprednisolone was the most popular drug for chronic progressive multiple sclerosis (76%; 70/92 of responders), the most often used regime being 1 g daily for 3 days (30 out of 65 who specified a dose). A course of oral prednisolone was the second most popular option (34%; 31/92). Courses varied greatly, ranging from starting doses of 15 to 60 mg tapering to zero over 12 to 84 or more days. Two consultants occasionally used long term oral prednisolone (more than 3 months) and two used alternate day dosing. Other corticosteroids recommended included dexamethasone (four) oral methylprednisolone (two), and ACTH (one). Five neurologists for whom it was applicable to answer the question did not do so, a further 28% (26/92) did not specify a dosage regime, although some recommended more than one course.
Use of corticosteroids for multiple sclerosis (MS) as recommended by consultant neurologists of the United Kingdom (n (%))
Discussion
Eighty six per cent of United Kingdom consultant neurologists would prescribe corticosteroids in a quarter or more cases of acute multiple sclerosis relapse; more than 99% would prescribe corticosteroids for acute multiple sclerosis relapse on some occasions. Therefore there was consensus that steroids should be prescribed for some relapses of multiple sclerosis, intravenous methylprednisolone being recommended in a fair proportion. No clear consensus was evident as to the type, duration, and dosage of corticosteroids or in their use for chronic multiple sclerosis. Evidence from randomised clinical trials confirms that corticosteroids are superior to placebo in accelerating recovery from relapses. The first trial in the 1960s found ACTH (not commercially available in the United Kingdom any more due to its variable and unpredictable therapeutic response) to be superior to placebo, 2 in two later trials intravenous methylprednisolone was found to be comparable or superior to ACTH. 3 4 Intravenous methylprednisolone (15 mg/kg/daily tapering to zero over 15 days (n=23), 5 or 500 mg daily for 5 days (n=50), 6 or 1g daily for 5 days (n=35) 7 has been shown to be more eVective than placebo. High dose intravenous methylprednisolone (5750 mg total over 14 days) has been shown to be comparable with intravenous dexamethasone (n=31) 8 (78 mg over 14 days; total equivalent anti-inflammatory dose being 390 mg methylprednisolone).
Patients in clinical trials, however, may not be representative of the population seen by neurologists in clinical practice. Reasons probably include variable access of patients with relapsing multiple sclerosis to specialist neurology services: some being seen at the height of relapse, others when the relapse has resolved or is obviously improving, and an unknown proportion of less severe episodes either being assessed by the general practitioner or not at all.
There is little evidence to advocate corticosteroids in chronic progressive multiple sclerosis, 6 7 9 although 45% of neurologists would do so at least occasionally, perhaps unconvinced by evidence based on small numbers. Alternatively there may be pressure to oVer "something" in an otherwise "hopeless" situation.
Ten per cent (20/206) of neurologists always recommended a tapering course of oral corticosteroids after intravenous methylprednisolone, with 25% (24/96) advocating a course lasting a month or more. Evidence for or against tapering oral corticosteroids after intravenous methylprednisolone is scant: increased side eVects have been found without measurable beneficial eVects. 5 Furthermore, the hypothalamic-pituitary-adrenal axis recovers suYciently after short term high dose intravenous methylprednisolone such that oral replacement therapy is not required for this reason. 10 Thus a short tapering course of oral corticosteroids seems justified only for a few patients clearly shown to relapse when a pulsed course of intravenous methylprednisolone is stopped.
Data from two recent clinical trials have suggested equivalence between oral and intravenous corticosteroids, 1 11 and although almost three quarters of neurologists recommended oral corticosteroids instead of intravenous methylprednisolone for acute multiple sclerosis relapse at sometime, only a minority (8%; 16/212) often or always did so. The most popular oral corticosteroid was prednisolone (66%; 103/156) starting at 60 mg, tapering to zero over 20 to 28 days (22%; 35/156), the regime recommended in one recent trial. 1 Fear was expressed that the prescribing of oral rather than intravenous corticosteroids for acute multiple sclerosis relapse would lead to chronic courses of corticosteroids 12 ; however, this was not substantiated by the results seen here. Only 6% (9/156) of respondents recommended oral corticosteroids for more than one month, although it is not known whether these recommendations are adhered to in practice, especially once the patient is under general practitioner supervision. Corticosteroids given orally have several advantages over those given intravenously-namely, reduced nursing and doctor time, reduced risk of infection (associated with intravenous administration), reduced necessity to admit to hospital, and an estimated cost saving of £472 000 per year in the United Kingdom (if all multiple sclerosis relapses were treated with oral prednisolone instead of intravenous methylprednisolone). 13 However, most neurologists remained unconvinced that oral instead of intravenous corticosteroids should be routinely prescribed; a larger randomised multicentre trial may clarify previous findings and help to rationalise practice.
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